

## Drug Monograph

Drug/Drug     **Auvi-Q<sup>®</sup> (epinephrine) Injection / alpha and beta-**  
 Class:         **adrenergic receptor agonist**  
 Prepared for: MO HealthNet  
 Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Auvi-Q<sup>®</sup> is available in two strengths of pre-filled auto-injector; 0.15 mg/0.15 mL and 0.3 mg/0.3 mL epinephrine injection.

**Manufacturer:** sanofi-aventis U.S. LLC Bridgewater, NJ 08807 A SANOFI COMPANY

**Indications:** Auvi-Q<sup>®</sup> is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis, idiopathic anaphylaxis or exercise-induced anaphylaxis.

**Costs:** \$120.50 per 2 pack of Auvi-Q. Wholesale Acquisition Cost

**Summary of Findings:** The Division recommends this product be considered for inclusion in the state specific Preferred Drug List and is currently under solicitation.

**Status Recommendation:**      Prior Authorization (PA) Required      Open Access  
     Fiscal Edit    PDL

**Type of PA Criteria:**            Increased Risk of ADE                                      Non-Preferred Agent  
     Appropriate Indications                                    Under Solicitation

Prepared By: Kathleen Wilbers, Pharm.D.  
 Date: May 13, 2013